Teva Pharmaceutical Industries Limited (TEVA) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Tel Aviv, Israel. The current CEO is Richard D. Francis.
TEVA has IPO date of 1982-02-16, 37,000 full-time employees, listed on the NYSE, a market capitalization of $36.99B.
Teva Pharmaceutical Industries Limited is a global pharmaceutical company headquartered in Tel Aviv, Israel, that develops, manufactures, and distributes generic medicines, specialty medicines, and biopharmaceutical products across North America, Europe, and international markets. The company operates across multiple therapeutic areas including central nervous system, pain, respiratory, and oncology, offering products in diverse dosage forms such as tablets, injectables, inhalants, and transdermal patches. Its portfolio includes well-known brands such as Copaxone for multiple sclerosis, AJOVY for migraine prevention, and AUSTEDO for movement disorders, alongside respiratory treatments including ProAir and QVAR for asthma and COPD, and oncology products such as Treanda and Granix. Teva also manufactures active pharmaceutical ingredients and collaborates with partners like MedinCell to develop long-acting injectable formulations. Founded in 1901, the company has established itself as a major player in the global pharmaceutical industry.
